COMMUNIQUÉS West-GlobeNewswire

Nox Peptides Introduces Educational Resources and Research Tools for Peptide Science
29/09/2026
TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nox Peptides has introduced a collection of educational resources and practical research tools designed to help readers and researchers better understand peptide science and [...]
Immunocine Names Janet Maendel, DO (EU), DNM, Director of Clinical Affairs
29/09/2026
Expanded role strengthens clinical interpretation, longitudinal patient assessment, and the scientific framework surrounding Immunocine’s Double-Loaded dendritic cell treatment program HOUSTON, Sept. 29, 2026 (GLOBE [...]
Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering
29/09/2026
SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a biomedical company developing and marketing products for the chronic wounds, [...]
Acquisition of Own Shares
29/09/2026
Mechelen, Belgium; 29 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
29/09/2026
WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29/09/2026
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation [...]
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
29/09/2026
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural [...]
Equillium Announces Poster Presentations at the 7th International AHR Conference
29/09/2026
New preclinical data further characterize EQ504’s effects on epithelial barrier repair and immune regulation LA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a biotechnology innovator [...]
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
29/09/2026
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
29/09/2026
RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Vireo Growth Inc. Announces Put/Call Agreement in Connection with Loan Acquisition
29/09/2026
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform, today announced that it has entered [...]
Pyxis Oncology Announces Proposed Public Offering
29/09/2026
BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a [...]
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
29/09/2026
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
HL7 Launches Break the Code to Build the Next Generation of Healthcare Interoperability Talent
29/09/2026
Free global program gives students hands-on experience building FHIR applications and earning HL7 credentials ANN ARBOR, Mich., Sept. 29, 2026 (GLOBE NEWSWIRE) -- With demand for healthcare interoperability expertise [...]
Aro Biotherapeutics Appoints Biotechnology Executive Brett Blackman, Ph.D., to its Board of Directors
29/09/2026
PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aro Biotherapeutics, a clinical-stage biotechnology company developing targeted short-interfering RNA (siRNA) medicines for the treatment of diseases with high unmet [...]
RESTEM to Present at the 2026 Cell & Gene Meeting on the Mesa
29/09/2026
MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that Chief [...]
Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting
29/09/2026
Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting Halle (Saale) / Munich, Germany, September 29 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a [...]
Regulated information: Disclosure of a transparency notification from BlackRock, Inc.
29/09/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2026 – 6 PM CET Disclosure of a transparency notification from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the [...]
Portsmouth Square, Inc. Reports Fiscal 2026 Results; Hotel Revenue Increases 20% Year-Over-Year and Operating Performance Strengthens as San Francisco Recovery Progresses
29/09/2026
Los Angeles, California, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. (the "Company" or "Portsmouth") financial results for the fiscal year ended June 30, 2026. Portsmouth operates in two reportable [...]

Pages